Article

Peering into the aftermath: The inhospitable host?

Sunnybrook Research Institute, Department of Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, Toronto, Canada.
Nature medicine (Impact Factor: 28.05). 10/2010; 16(10):1084-5. DOI: 10.1038/nm1010-1084
Source: PubMed
0 Bookmarks
 · 
64 Views
  • Journal of Clinical Oncology 08/2013; · 17.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aerobic exercise training (AET) is an effective adjunct therapy to attenuate the adverse side-effects of adjuvant chemotherapy in women with early breast cancer. Whether AET interacts with the antitumor efficacy of chemotherapy has received scant attention. We conducted a pilot study to explore the effects of AET in combination with neoadjuvant doxorubicin - cyclophosphamide (AC+AET), relative to AC alone, on: (i) host physiology [exercise capacity (VO2peak), brachial artery flow-mediated dilatation (BA-FMD)], (ii) host-related circulating factors [circulating endothelial progenitor cells (CEPs) cytokines and angiogenic factors (CAFs)], and (iii) tumor phenotype [tumor blood flow (15O-water PET), tissue markers (hypoxia, proliferation), and gene expression] in 20 women with operable breast cancer. AET consisted of three supervised cycle ergometry sessions / week at 60% to 100% of VO2peak, 30-45 min/session, for 12 weeks. There was significant time x group interactions for VO2peak and BA-FMD, favoring the AC+AET group (p<0.001 and p=0.07, respectively). These changes were accompanied by significant time x group interactions in CEPs and select CAFs (placenta growth factor, interleukin (IL)-1β, and IL-2), also favoring the AC+AET group (p's<0.05). 15O-water PET imaging revealed a 38% decrease in tumor blood flow in the AC+AET group. There were no differences in any tumor tissue markers (p's>0.05). Whole-genome microarray tumor analysis revealed significant differential modulation of 57 pathways (p's<0.01), including many that converge on NF-κB. Data from this exploratory study provide initial evidence that AET can modulate several host and tumor-related pathways during standard chemotherapy. The biological and clinical implications remain to be determined.
    Cancer Prevention Research 07/2013; · 4.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We previously reported that the host response to certain chemotherapies can induce primary tumor regrowth, angiogenesis, and even metastases in mice, but the possible impact of anti-vascular endothelial growth factor-A (VEGF-A) therapy in this context has not been fully explored. We therefore used combinations of anti-VEGF-A with chemotherapy on various tumor models in mice including primary tumors, experimental lung metastases, and spontaneous lung metastases of 4T1-breast and CT26-colon murine cancer cell lines. Our results show that a combined treatment with anti-VEGF-A and folinic acid/5-fluorouracil/oxaliplatin (FOLFOX) but not with anti-VEGF-A and gemcitabine/cisplatinum (Gem/CDDP) enhances the treatment outcome partly due to reduced angiogenesis, in both primary tumors and in experimental lung metastases models. However, neither treatment group exhibited an improved treatment outcome in the spontaneous lung metastases model nor were changes in endothelial cell numbers found at metastatic sites. Since chemotherapy has recently been shown to induce tumor cell invasion, we tested the invasion properties of tumor cells when exposed to plasma from FOLFOX-treated mice or cancer patients. While plasma from FOLFOX-treated mice or patients induced invasion properties of tumor cells, the combination of anti-VEGF-A and FOLFOX abrogated these effects, despite the reduced plasma VEGF-A levels detected in FOLFOX-treated mice. These results suggest that the therapeutic impact of antiangiogenic drugs varies in different tumor models, and that anti-VEGF-A therapy can block the invasion properties of tumor cells in response to chemotherapy. These results may implicate an additional therapeutic role for anti-VEGF-A when combined with chemotherapy.
    Molecular Cancer Therapeutics 10/2013; · 5.60 Impact Factor

Full-text (2 Sources)

Download
8 Downloads
Available from
Oct 18, 2014